Increasing access to cancer trials in Minnesota (InACT-MN)

增加明尼苏达州癌症试验的机会 (InACT-MN)

• 批准号: 10636408
• 负责人: Britt Kristina Erickson
• 金额: $ 18.28万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-18 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10636408
• 关键词: Area; Body of uterus; Cancer Burden; Cancer Center; Cancer Control; Cause of Death; Clinical; Clinical Trials; Clinical Trials Design; Clinical Trials Network; Collaborations; Communities; Community Medicine; Development; Disease; ERBB2 gene; Endometrial Carcinoma; Enrollment; Exemestane; Funding; Gynecologic Oncology; Health; Improve Access; Infrastructure; Knowledge; Leadership; Location; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Mentors; Minnesota; Mission; Native Americans; Oncologist; Oncology; Patients; Phase; Population; Prevention trial; Principal Investigator; Process; Protocols documentation; Research; Review Committee; Role; Rural; Services; Site; Specialist; Therapeutic Clinical Trial; Therapeutic Trials; Treatment outcome; Universities; University of Minnesota Cancer Center; Vision; Work; cancer clinical trial; cancer health disparity; cancer prevention; experience; health care delivery; improved; innovation; member; mentoring community; metropolitan; novel; public health relevance; service delivery; skills; success

PROJECT SUMMARY/ABSTRACT In collaboration with the Masonic Cancer Center of the University of Minnesota, Britt Erickson, MD, has developed a research strategy that will leverage her skills in clinical trial design and execution, as well as her experience as a mentor and educator, to improve access to NCI clinical trials within the Masonic Cancer Center and throughout greater Minnesota. She will open and enroll to more NCI prevention and therapeutic trials in gynecologic oncology. She will collaborate with other disease site leaders and cooperative group principal investigators in order to prioritize trials with the highest chances for success at the University of Minnesota. She will be the community clinical trial liaison for the Masonic Cancer Center, opening gynecologic oncology specific NCI trials at community sites and mentoring community oncologists in the process of clinical trial leadership and accrual. This community extension will be done through the M Health Fairview Cancer Service Line, a novel clinical entity established in 2019 as a result of combining efforts between the University of Minnesota and Fairview, a non- profit healthcare delivery service. The M Health Fairview Cancer Service Line includes seven community sites throughout the Minneapolis/St Paul metropolitan area and presents an opportunity to break down traditional barriers between academic and community medicine, uniting with a common vision of increasing access to therapeutic clinical trials. The Cancer Service Line has also extended to two underserved sites in rural central Minnesota with a substantial Native American population and historically limited clinical trial access. At these locations—working with community oncologists, existing NCORP infrastructure, and pre-existing collaborations through the Minnesota Cancer Clinical Trials Network (a state funded network since 2017, housed at the University of Minnesota)—Dr. Erickson will be integral to the mission of expanding NCI clinical trial access to all Minnesotans. Dr. Erickson’s experience and current involvement locally and nationally in NCI clinical trial work make her an ideal candidate for the proposed plan. In addition to expanding trial availability, she will continue her local and national service. This includes serving as a member of the Cancer Protocol Review Committee and as co-chair of the Gynecologic Oncology Interdisciplinary Site Committee within the Masonic Cancer Center. It also involves serving as a core member of the Uterine Corpus Committee and Cancer Prevention and Control Committee of NRG oncology. She will also continue her work as the national PI of the phase II DCP trial of exemestane in endometrial cancer (UWI-2016-08-01) and national PI of a new cooperative group study, NRG- GY026, which is exploring the role of HER2 directed therapy in HER2 positive endometrial cancer, set to open in June of 2022 with planned accrual of 525 patients.

项目总结/摘要 医学博士布里特埃里克森与明尼苏达大学共济会癌症中心合作， 开发了一种研究策略，将利用她在临床试验设计和执行方面的技能，以及她的 作为导师和教育工作者的经验，以提高获得共济会癌症内的NCI临床试验 以及整个明尼苏达州。 她将开放和招募更多的NCI预防和治疗妇科肿瘤的试验。她将 与其他疾病现场负责人和合作小组主要研究者合作，以确定优先顺序 明尼苏达大学最有可能成功的试验。她将是社区诊所 共济会癌症中心的试验联络员，在社区开展妇科肿瘤特异性NCI试验 在临床试验领导和收益过程中指导社区肿瘤学家。这 社区扩展将通过M健康费尔维尤癌症服务线，一个新的临床实体进行 成立于2019年，是明尼苏达大学和费尔维尤大学共同努力的结果，费尔维尤大学是一个非 盈利的医疗保健服务。M Health Fairview癌症服务热线包括七个社区站点 整个明尼阿波利斯/圣保罗大都市区，并提供了一个机会，打破传统的 学术和社区医学之间的障碍，团结一致，共同愿景是增加获得 治疗性临床试验癌症服务热线还延伸到了农村中心的两个服务不足的地点。 明尼苏达州有大量的美洲原住民人口，历史上临床试验准入有限。在这些 地点-与社区肿瘤学家、现有的NCORP基础设施和预先存在的合作 通过明尼苏达州癌症临床试验网络（自2017年以来由州政府资助的网络，位于 埃里克森博士将是扩大NCI临床试验准入的使命不可或缺的一部分， 都是明尼苏达人 博士埃里克森的经验和目前参与当地和全国的NCI临床试验工作，使她成为一个 理想的候选人为拟议的计划。除了扩大试用范围外，她还将继续在当地和 国家服务。这包括担任癌症议定书审查委员会成员和共同主席 共济会癌症中心妇科肿瘤学跨学科现场委员会。它还 包括担任子宫体委员会和癌症预防和控制的核心成员 NRG肿瘤学委员会。她还将继续作为DCP II期试验的国家PI开展工作， 子宫内膜癌中的依西美坦（UWI-2016-08-01）和一项新的合作组研究的国家PI，NRG- GY 026正在探索HER 2导向治疗在HER 2阳性子宫内膜癌中的作用， 2022年6月，计划招募525名患者。